174 related articles for article (PubMed ID: 35016744)
21. [Association of genetic polymorphisms of key molecules in JAK/STAT signaling pathway with susceptibility of hepatocellular carcinoma].
Xie JX; Yin JH; Zhang Q; Pu R; Zhang YW; Lu WY; Cao GW
Zhonghua Liu Xing Bing Xue Za Zhi; 2012 Feb; 33(2):215-9. PubMed ID: 22575147
[TBL] [Abstract][Full Text] [Related]
22. Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI.
Park K; Lee JL; Park I; Park S; Ahn Y; Ahn JH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
Med Oncol; 2012 Dec; 29(5):3291-7. PubMed ID: 22460837
[TBL] [Abstract][Full Text] [Related]
23. [mTOR inhibitors].
Oya M
Nihon Rinsho; 2010 Jun; 68(6):1067-71. PubMed ID: 20535957
[TBL] [Abstract][Full Text] [Related]
24. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
[TBL] [Abstract][Full Text] [Related]
25. [Associations between gene polymorphisms of signal transducer and activator of transcription 3 and the susceptibility to hepatitis B virus related liver cirrhosis].
Yan XH; Wu JL; Yu R; Ma XH; Li QF; Xie RF
Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Feb; 56(2):185-191. PubMed ID: 35184448
[TBL] [Abstract][Full Text] [Related]
26. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
27. Morphoproteomics and biomedical analytics confirm the mTORC2/Akt pathway as a resistance signature and activated ERK and STAT3 as concomitant prosurvival/antiapoptotic pathways in metastatic renal cell carcinoma (RCC) progressing on rapalogs: pathogenesis and therapeutic options.
Brown RE; Buryanek J; Tammisetti VS; McGuire MF; Csencsits-Smith K
Oncotarget; 2016 Jul; 7(27):41612-41621. PubMed ID: 27223432
[TBL] [Abstract][Full Text] [Related]
28. First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium.
Harshman LC; Kroeger N; Rha SY; Donskov F; Wood L; Tantravahi SK; Vaishampayan U; Rini BI; Knox J; North S; Ernst S; Yuasa T; Srinivas S; Pal S; Heng DY; Choueiri TK
Clin Genitourin Cancer; 2014 Oct; 12(5):335-40. PubMed ID: 24787966
[TBL] [Abstract][Full Text] [Related]
29. PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.
Roldan-Romero JM; Beuselinck B; Santos M; Rodriguez-Moreno JF; Lanillos J; Calsina B; Gutierrez A; Tang K; Lainez N; Puente J; Castellano D; Esteban E; Climent MA; Arranz JA; Albersen M; Oudard S; Couchy G; Caleiras E; Montero-Conde C; Cascón A; Robledo M; Rodríguez-Antona C; García-Donas J;
Int J Cancer; 2020 Mar; 146(5):1435-1444. PubMed ID: 31335987
[TBL] [Abstract][Full Text] [Related]
30. STAT3 and STAT5b polymorphism contributes to breast cancer risk and clinical outcomes.
Zhao L; Zhang Q; Luan X; Huang X; Zhao S; Zhao H
Int J Clin Exp Pathol; 2015; 8(2):2033-8. PubMed ID: 25973100
[TBL] [Abstract][Full Text] [Related]
31. Calcitriol inhibits migration and invasion of renal cell carcinoma cells by suppressing Smad2/3-, STAT3- and β-catenin-mediated epithelial-mesenchymal transition.
Xu S; Zhang ZH; Fu L; Song J; Xie DD; Yu DX; Xu DX; Sun GP
Cancer Sci; 2020 Jan; 111(1):59-71. PubMed ID: 31729097
[TBL] [Abstract][Full Text] [Related]
32. STAT3 polymorphisms and IL-6 polymorphism are associated with the risk of basal cell carcinoma in patients from northern Poland.
Sławińska M; Zabłotna M; Gleń J; Lakomy J; Nowicki RJ; Sobjanek M
Arch Dermatol Res; 2019 Nov; 311(9):697-704. PubMed ID: 31342143
[TBL] [Abstract][Full Text] [Related]
33. Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.
Powles T; Lackner MR; Oudard S; Escudier B; Ralph C; Brown JE; Hawkins RE; Castellano D; Rini BI; Staehler MD; Ravaud A; Lin W; O'Keeffe B; Wang Y; Lu S; Spoerke JM; Huw LY; Byrtek M; Zhu R; Ware JA; Motzer RJ
J Clin Oncol; 2016 May; 34(14):1660-8. PubMed ID: 26951309
[TBL] [Abstract][Full Text] [Related]
34. Energy balance, polymorphisms in the mTOR pathway, and renal cell carcinoma risk.
Shu X; Lin J; Wood CG; Tannir NM; Wu X
J Natl Cancer Inst; 2013 Mar; 105(6):424-32. PubMed ID: 23378641
[TBL] [Abstract][Full Text] [Related]
35. mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm.
Willemsen AE; Grutters JC; Gerritsen WR; van Erp NP; van Herpen CM; Tol J
Int J Cancer; 2016 May; 138(10):2312-21. PubMed ID: 26452336
[TBL] [Abstract][Full Text] [Related]
36. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma.
Cho DC; Cohen MB; Panka DJ; Collins M; Ghebremichael M; Atkins MB; Signoretti S; Mier JW
Clin Cancer Res; 2010 Jul; 16(14):3628-38. PubMed ID: 20606035
[TBL] [Abstract][Full Text] [Related]
37. Current data with mammalian target of rapamycin inhibitors in advanced-stage renal cell carcinoma.
Reddy GK; Mughal TI; Rini BI
Clin Genitourin Cancer; 2006 Sep; 5(2):110-3. PubMed ID: 17026798
[TBL] [Abstract][Full Text] [Related]
38. FOXP3 polymorphisms in interstitial lung disease among Chinese Han population: A genetic association study.
Yao J; Zhang T; Zhang L; Han K; Zhang L
Clin Respir J; 2018 Mar; 12(3):1182-1190. PubMed ID: 28508461
[TBL] [Abstract][Full Text] [Related]
39. Mechanism of gypenosides of Gynostemma pentaphyllum inducing apoptosis of renal cell carcinoma by PI3K/AKT/mTOR pathway.
Liu H; Li X; Duan Y; Xie JB; Piao XL
J Ethnopharmacol; 2021 May; 271():113907. PubMed ID: 33556477
[TBL] [Abstract][Full Text] [Related]
40. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
